MedTrace Logo

Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy

NCT05101759 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-09-25

No results posted yet for this study

Summary

The aim of the study is to assess the prevalence of functional decline in elderly patients treated with chemotherapy or immunochemotherapy for lymphoid hematologic malignancies. For this purpose, each patient benefits at inclusion (D0) of a standardized gerontological evaluation, and 3 and 6 months post-inclusion.

Conditions

Interventions

PROCEDURE

Comprehensive Geriatric Assessment

A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.

Sponsors & Collaborators

  • Institut Claudius Regaud

    collaborator OTHER

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Laurent BALARDY, MD · University Hospital, Toulouse

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2024-09-16
Completion
2024-09-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101759 on ClinicalTrials.gov